Adrian R. Krainer is Director at Stoke Therapeutics, Inc. (STOK). They have made 1 open-market trade across 1 company since 2025, most recently 2026-03-10.
CIK 0001780081
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| STOK | 283,302 | $6.9M |
Shares reported on the most recent Form 4, priced at the 2026-03-12 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| STOK | SELL | 2026-03-10 | 2026-03-12 | $39.74 | $1.3M | -12.6% | -4.8% | -22.7% |
| STOK | SELL · 10b5-1 | 2026-03-02 | 2026-03-04 | $39.66 | $287K | +0.7% | -2.8% | -15.0% |
| STOK | SELL · 10b5-1 | 2025-11-24 | 2025-11-26 | $29.72 | $2.4M | -2.4% | +2.2% | +13.7% |
| STOK | SELL · 10b5-1 | 2025-11-14 | 2025-11-18 | $26.98 | $2.2M | +4.0% | +10.4% | +7.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.